{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:39:47Z","timestamp":1793741987889,"version":"4.6.1"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"DOI":"10.1038\/s41571-019-0184-6","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T05:05:32Z","timestamp":1551762332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":447,"title":["Mechanisms of resistance to CAR T cell therapy"],"prefix":"10.1038","author":[{"given":"Nirali N.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5226","authenticated-orcid":false,"given":"Terry J.","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,5]]},"reference":[{"key":"184_CR1","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl Med. 3, 95ra73 (2011).","journal-title":"Sci. Transl Med."},{"key":"184_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"184_CR3","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).","journal-title":"Blood"},{"key":"184_CR4","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"184_CR5","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMp1711886","volume":"377","author":"L Rosenbaum","year":"2017","unstructured":"Rosenbaum, L. Tragedy, perseverance, and chance \u2014 the story of CAR-T therapy. N. Engl. J. Med. 377, 1313\u20131315 (2017).","journal-title":"N. Engl. J. Med."},{"key":"184_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"184_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"184_CR8","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2016-10-748772","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner, R. A. et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322\u20133331 (2017).","journal-title":"Blood"},{"key":"184_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"184_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"184_CR11","unstructured":"US Food & Drug Administration. FDA approves CAR-T cell therapy to treat adults with certain types of large B cell lymphoma. FDA https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm581216.htm (2017)."},{"key":"184_CR12","unstructured":"US Food & Drug Administration. FDA approval brings\u00a0first gene therapy to the United States. FDA\u00a0 https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm574058.htm (2017)."},{"key":"184_CR13","unstructured":"US Food & Drug Administration. FDA approves tisagenlecleucel for adults with relapsed or refractory large B cell lymphoma. FDA https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm606540.htm (2018)."},{"key":"184_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrd.2018.74","volume":"17","author":"J Tang","year":"2018","unstructured":"Tang, J., Hubbard-Lucey, V. M., Pearce, L., O\u2019Donnell-Tormey, J. & Shalabi, A. The global landscape of cancer cell therapy. Nat. Rev. Drug Discov. 17, 465\u2013466 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"184_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"184_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","volume":"7","author":"E Jacoby","year":"2016","unstructured":"Jacoby, E. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun. 7, 12320 (2016).","journal-title":"Nat. Commun."},{"key":"184_CR17","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T cell therapy. Blood 127, 2406\u20132410 (2016).","journal-title":"Blood"},{"key":"184_CR18","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","volume":"130","author":"KT Mueller","year":"2017","unstructured":"Mueller, K. T. et al. Cellular kinetics of CTL019 in relapsed\/refractory B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130, 2317\u20132325 (2017).","journal-title":"Blood"},{"key":"184_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1160-5","volume":"15","author":"DF Stroncek","year":"2017","unstructured":"Stroncek, D. F. et al. Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. J. Transl Med. 15, 59 (2017).","journal-title":"J. Transl Med."},{"key":"184_CR20","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/trf.14569","volume":"58","author":"F Ceppi","year":"2018","unstructured":"Ceppi, F. et al. Lymphocyte apheresis for chimeric antigen receptor T cell manufacturing in children and young adults with leukemia and neuroblastoma. Transfusion 58, 1414\u20131420 (2018).","journal-title":"Transfusion"},{"issue":"Suppl","key":"184_CR21","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1538-7445.AM2018-1631","volume":"78","author":"RK Das","year":"2018","unstructured":"Das, R. K., Storm, J. & Barrett, D. M. T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential. Cancer Res. 78 (Suppl), 1631 (2018).","journal-title":"Cancer Res."},{"key":"184_CR22","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","volume":"8","author":"N Singh","year":"2016","unstructured":"Singh, N., Perazzelli, J., Grupp, S. A. & Barrett, D. M. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci. Transl Med. 8, 320ra3 (2016).","journal-title":"Sci. Transl Med."},{"key":"184_CR23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1182\/blood-2012-08-449413","volume":"122","author":"H Zhang","year":"2013","unstructured":"Zhang, H. et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 122, 1105\u20131113 (2013).","journal-title":"Blood"},{"key":"184_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fonc.2014.00349","volume":"4","author":"K Veirman De","year":"2014","unstructured":"De Veirman, K. et al. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front. Oncol. 4, 349 (2014).","journal-title":"Front. Oncol."},{"key":"184_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4, 92\u2013101 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"184_CR26","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang, X. & Riviere, I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol. Ther. Oncolyt. 3, 16015 (2016).","journal-title":"Mol. Ther. Oncolyt."},{"key":"184_CR27","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jcyt.2013.06.003","volume":"15","author":"B Tumaini","year":"2013","unstructured":"Tumaini, B. et al. Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy 15, 1406\u20131415 (2013).","journal-title":"Cytotherapy"},{"key":"184_CR28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"JN Kochenderfer","year":"2009","unstructured":"Kochenderfer, J. N. et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689\u2013702 (2009).","journal-title":"J. Immunother."},{"key":"184_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jcyt.2014.12.002","volume":"17","author":"T Gargett","year":"2015","unstructured":"Gargett, T. & Brown, M. P. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Cytotherapy 17, 487\u2013495 (2015).","journal-title":"Cytotherapy"},{"key":"184_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8\u2009+\u2009and CD4\u2009+\u2009subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492\u2013500 (2016).","journal-title":"Leukemia"},{"key":"184_CR31","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4\u2009+\u2009:CD8\u2009+\u2009composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"184_CR32","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.2147\/DDDT.S175113","volume":"12","author":"W Zhang","year":"2018","unstructured":"Zhang, W., Jordan, K. R., Schulte, B. & Purev, E. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. Drug Des. Devel Ther. 12, 3343\u20133356 (2018).","journal-title":"Drug Des. Devel Ther."},{"key":"184_CR33","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","volume":"20","author":"F Zhu","year":"2018","unstructured":"Zhu, F. et al. Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy 20, 394\u2013406 (2018).","journal-title":"Cytotherapy"},{"key":"184_CR34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","volume":"128","author":"M Sabatino","year":"2016","unstructured":"Sabatino, M. et al. Generation of clinical-grade CD19-specific CAR-modified CD8\u2009+\u2009memory stem cells for the treatment of human B cell malignancies. Blood 128, 519\u2013528 (2016).","journal-title":"Blood"},{"key":"184_CR35","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00262-018-2155-7","volume":"67","author":"F Blaeschke","year":"2018","unstructured":"Blaeschke, F. et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4(\u2009+\u2009) and CD8(\u2009+\u2009) CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19(\u2009+\u2009) acute lymphoblastic leukemia. Cancer Immunol. Immunother. 67, 1053\u20131066 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"184_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"184_CR37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","volume":"18","author":"DF Stroncek","year":"2016","unstructured":"Stroncek, D. F. et al. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy 18, 893\u2013901 (2016).","journal-title":"Cytotherapy"},{"key":"184_CR38","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"184_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.tmrv.2016.03.001","volume":"30","author":"A Fesnak","year":"2016","unstructured":"Fesnak, A., Lin, C., Siegel, D. L. & Maus, M. V. CAR-T cell therapies from the transfusion medicine perspective. Transfus. Med. Rev. 30, 139\u2013145 (2016).","journal-title":"Transfus. Med. Rev."},{"key":"184_CR40","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1182\/blood-2017-09-804070","volume":"130","author":"NN Shah","year":"2017","unstructured":"Shah, N. N. et al. CD4\/CD8 T-cell selection enhances CD22 CAR-T cell transduction and in-vivo CAR-T expansion: updated results on phase I anti-CD22 CAR dose expansion cohort. Blood 130, 809 (2017).","journal-title":"Blood"},{"key":"184_CR41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","volume":"53","author":"P Vormittag","year":"2018","unstructured":"Vormittag, P., Gunn, R., Ghorashian, S. & Veraitch, F. S. A guide to manufacturing CAR T cell therapies. Curr. Opin. Biotechnol. 53, 164\u2013181 (2018).","journal-title":"Curr. Opin. Biotechnol."},{"key":"184_CR42","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.bbmt.2018.02.018","volume":"24","author":"K Perica","year":"2018","unstructured":"Perica, K., Curran, K. J., Brentjens, R. J. & Giralt, S. A. Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center. Biol. Blood Marrow Transplant. 24, 1135\u20131141 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"184_CR43","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380\u2013390 (2016).","journal-title":"Immunity"},{"key":"184_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"184_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ Stegen van der","year":"2015","unstructured":"van der Stegen, S. J., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 14, 499\u2013509 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"184_CR46","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ymthe.2017.09.008","volume":"26","author":"K Cornetta","year":"2018","unstructured":"Cornetta, K. et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. Mol. Ther. 26, 280\u2013288 (2018).","journal-title":"Mol. Ther."},{"key":"184_CR47","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.omtm.2018.08.006","volume":"10","author":"K Cornetta","year":"2018","unstructured":"Cornetta, K. et al. Screening clinical cell products for replication competent retrovirus: the National Gene Vector Biorepository experience. Mol. Ther. Methods Clin. Dev. 10, 371\u2013378 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"184_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/CAD.0000000000000387","volume":"27","author":"DY Qin","year":"2016","unstructured":"Qin, D. Y. et al. Paralleled comparison of vectors for the generation of CAR-T cells. Anticancer Drugs 27, 711\u2013722 (2016).","journal-title":"Anticancer Drugs"},{"key":"184_CR49","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1089\/hgtb.2017.083","volume":"28","author":"V Golumba-Nagy","year":"2017","unstructured":"Golumba-Nagy, V., Kuehle, J. & Abken, H. Genetic modification of T cells with chimeric antigen receptors: a laboratory manual. Hum. Gene Ther. Methods 28, 302\u2013309 (2017).","journal-title":"Hum. Gene Ther. Methods"},{"key":"184_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-1-62703-260-5_12","volume":"969","author":"T Riet","year":"2013","unstructured":"Riet, T. et al. Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. Methods Mol. Biol. 969, 187\u2013201 (2013).","journal-title":"Methods Mol. Biol."},{"key":"184_CR51","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/mt.2016.146","volume":"24","author":"MK Panjwani","year":"2016","unstructured":"Panjwani, M. K. et al. Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Mol. Ther. 24, 1602\u20131614 (2016).","journal-title":"Mol. Ther."},{"key":"184_CR52","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/leu.2016.180","volume":"31","author":"R Monjezi","year":"2017","unstructured":"Monjezi, R. et al. Enhanced CAR T cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia 31, 186\u2013194 (2017).","journal-title":"Leukemia"},{"key":"184_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/imr.12137","volume":"257","author":"H Singh","year":"2014","unstructured":"Singh, H., Huls, H., Kebriaei, P. & Cooper, L. J. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol. Rev. 257, 181\u2013190 (2014).","journal-title":"Immunol. Rev."},{"key":"184_CR54","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei, P. et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J. Clin. Invest. 126, 3363\u20133376 (2016).","journal-title":"J. Clin. Invest."},{"key":"184_CR55","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jcyt.2018.01.011","volume":"20","author":"C Wolf de","year":"2018","unstructured":"de Wolf, C., van de Bovenkamp, M. & Hoefnagel, M. Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy. Cytotherapy 20, 601\u2013622 (2018).","journal-title":"Cytotherapy"},{"key":"184_CR56","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jcyt.2017.12.007","volume":"20","author":"J Xu","year":"2018","unstructured":"Xu, J., Melenhorst, J. J. & Fraietta, J. A. Toward precision manufacturing of immunogene T cell therapies. Cytotherapy 20, 623\u2013638 (2018).","journal-title":"Cytotherapy"},{"key":"184_CR57","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2018-03-835413","volume":"132","author":"J Rossi","year":"2018","unstructured":"Rossi, J. et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood 132, 804\u2013814 (2018).","journal-title":"Blood"},{"key":"184_CR58","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nm.4258","volume":"23","author":"A Ghosh","year":"2017","unstructured":"Ghosh, A. et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat. Med. 23, 242\u2013249 (2017).","journal-title":"Nat. Med."},{"key":"184_CR59","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112\u20131121 (2016).","journal-title":"J. Clin. Oncol."},{"key":"184_CR60","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/bjh.14923","volume":"179","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br. J. Haematol. 179, 598\u2013605 (2017).","journal-title":"Br. J. Haematol."},{"key":"184_CR61","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer, J. N. et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129\u20134139 (2013).","journal-title":"Blood"},{"key":"184_CR62","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","volume":"26","author":"C Georgiadis","year":"2018","unstructured":"Georgiadis, C. et al. Long terminal repeat CRISPR-CAR-coupled \u201cuniversal\u201d T cells mediate potent anti-leukemic effects. Mol. Ther. 26, 1215\u20131227 (2018).","journal-title":"Mol. Ther."},{"key":"184_CR63","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot, L. et al. Multiplex genome-edited T cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T cell immunotherapies. Cancer Res. 75, 3853\u20133864 (2015).","journal-title":"Cancer Res."},{"key":"184_CR64","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper, M. L. et al. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 32, 1970\u20131983 (2018).","journal-title":"Leukemia"},{"key":"184_CR65","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","volume":"51","author":"M Daher","year":"2018","unstructured":"Daher, M. & Rezvani, K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr. Opin. Immunol. 51, 146\u2013153 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"184_CR66","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang, X. et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am. J. Cancer Res. 8, 1083\u20131089 (2018).","journal-title":"Am. J. Cancer Res."},{"key":"184_CR67","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03579927 (2019)."},{"issue":"Suppl. 1","key":"184_CR68","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood-2018-99-118005","volume":"132","author":"C Quintarelli","year":"2018","unstructured":"Quintarelli, C. et al. CD19 redirected CAR NK cells are equally effective but less toxic than CAR T cells. Blood 132 (Suppl. 1), 3491 (2018).","journal-title":"Blood"},{"key":"184_CR69","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3389\/fimmu.2017.00745","volume":"8","author":"E Hofer","year":"2017","unstructured":"Hofer, E. & Koehl, U. Natural killer cell-based cancer immunotherapies: from immune evasion to promising targeted cellular therapies. Front. Immunol. 8, 745 (2017).","journal-title":"Front. Immunol."},{"key":"184_CR70","unstructured":"US Food & Drug Administration. Package insert \u2014 Kymriah. FDA https:\/\/www.fda.gov\/downloads\/UCM573941.pdf (2018)."},{"key":"184_CR71","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"184_CR72","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41434-018-0019-6","volume":"25","author":"KL Lowe","year":"2018","unstructured":"Lowe, K. L. et al. Fludarabine and neurotoxicity in engineered T cell therapy. Gene Ther. 25, 176\u2013191 (2018).","journal-title":"Gene Ther."},{"key":"184_CR73","unstructured":"Novartis. Kymriah treatment center locator. Kymriah https:\/\/www.us.kymriah.com\/treatment-center-locator\/ (2018)."},{"key":"184_CR74","unstructured":"Kite Pharma. Where can Yescarta be received? Yescarta https:\/\/www.yescarta.com\/treatment-centers (2018)."},{"key":"184_CR75","unstructured":"European Medicines Agency. First two CAR-T cell medicines recommended for approval in the European Union. EMA https:\/\/www.ema.europa.eu\/en\/news\/first-two-car-t-cell-medicines-recommended-approval-european-union (2018)."},{"key":"184_CR76","unstructured":"Novartis Pharmaceuticals Canada Inc. Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah\u2122 (tisagenlecleucel)i. Newswire https:\/\/www.newswire.ca\/news-releases\/novartis-receives-health-canada-approval-of-its-car-t-cell-therapy-kymriah-tisagenlecleuceli-692581041.html (2018)."},{"key":"184_CR77","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"184_CR78","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11899-018-0444-z","volume":"13","author":"GL Shah","year":"2018","unstructured":"Shah, G. L., Majhail, N., Khera, N. & Giralt, S. Value-based care in hematopoietic cell transplantation and cellular therapy: challenges and opportunities. Curr. Hematol. Malig. Rep. 13, 125\u2013134 (2018).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"184_CR79","unstructured":"Caffrey, M. With approval of CAR T-cell therapy comes the next challenge: payer coverage. Am. J. Manag. Care https:\/\/www.ajmc.com\/journals\/evidence-based-oncology\/2018\/february-2018\/with-approval-of-car-tcell-therapy-comes-the-next-challenge-payer-coverage (2018)."},{"key":"184_CR80","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMp1807382","volume":"379","author":"PB Bach","year":"2018","unstructured":"Bach, P. B. National coverage analysis of CAR-T therapies \u2014 policy, evidence, and payment. N. Engl. J. Med. 379, 1396\u20131398 (2018).","journal-title":"N. Engl. J. Med."},{"key":"184_CR81","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2018-99-115351","volume":"132","author":"H Kotani","year":"2018","unstructured":"Kotani, H. et al. Aged CAR T cells exhibit enhanced cytotoxicity and effector function but shorter persistence and less memory-like phenotypes. Blood 132, 2047 (2018).","journal-title":"Blood"},{"key":"184_CR82","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2018-99-117493","volume":"132","author":"R Gardner","year":"2018","unstructured":"Gardner, R. et al. Starting T cell and cell product phenotype are associated with durable remission of leukemia following CD19 CAR-T cell immunotherapy. Blood 132, 4022 (2018).","journal-title":"Blood"},{"key":"184_CR83","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak, A. D., June, C. H. & Levine, B. L. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 16, 566\u2013581 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"184_CR84","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"184_CR85","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B cell lymphoma and indolent B cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540\u2013549 (2015).","journal-title":"J. Clin. Oncol."},{"key":"184_CR86","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl Med. 6, 224ra25 (2014).","journal-title":"Sci. Transl Med."},{"key":"184_CR87","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"184_CR88","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2018","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2018).","journal-title":"Nat. Med."},{"key":"184_CR89","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain, M., Brentjens, R. & Riviere, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388\u2013398 (2013).","journal-title":"Cancer Discov."},{"key":"184_CR90","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","volume":"22","author":"MV Maus","year":"2016","unstructured":"Maus, M. V. & June, C. H. Making better chimeric antigen receptors for adoptive T cell therapy. Clin. Cancer Res. 22, 1875\u20131884 (2016).","journal-title":"Clin. Cancer Res."},{"key":"184_CR91","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"184_CR92","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"184_CR93","first-page":"717","volume":"41","author":"IY Jung","year":"2018","unstructured":"Jung, I. Y. & Lee, J. Unleashing the therapeutic potential of CAR-T cell therapy using gene-editing technologies. Mol. Cells 41, 717\u2013723 (2018).","journal-title":"Mol. Cells"},{"key":"184_CR94","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature21506","volume":"543","author":"MV Maus","year":"2017","unstructured":"Maus, M. V. Immunology: T cell tweaks to target tumours. Nature 543, 48\u201349 (2017).","journal-title":"Nature"},{"key":"184_CR95","first-page":"130","volume":"4","author":"AN Hasan","year":"2015","unstructured":"Hasan, A. N., Selvakumar, A. & O\u2019Reilly, R. J. Artificial antigen presenting cells: an off the shelf approach for generation of desirable T-cell populations for broad application of adoptive immunotherapy. Adv. Genet. Eng. 4, 130 (2015).","journal-title":"Adv. Genet. Eng."},{"key":"184_CR96","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/PPO.0b013e3181eb33a6","volume":"16","author":"CJ Turtle","year":"2010","unstructured":"Turtle, C. J. & Riddell, S. R. Artificial antigen-presenting cells for use in adoptive immunotherapy. Cancer J. 16, 374\u2013381 (2010).","journal-title":"Cancer J."},{"key":"184_CR97","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/imr.12129","volume":"257","author":"MO Butler","year":"2014","unstructured":"Butler, M. O. & Hirano, N. Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol. Rev. 257, 191\u2013209 (2014).","journal-title":"Immunol. Rev."},{"key":"184_CR98","doi-asserted-by":"publisher","first-page":"E340","DOI":"10.3390\/ijms19020340","volume":"19","author":"DH Yoon","year":"2018","unstructured":"Yoon, D. H., Osborn, M. J., Tolar, J. & Kim, C. J. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T. Int. J. Mol. Sci. 19, E340 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"184_CR99","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130\u20133144 (2016).","journal-title":"J. Clin. Invest."},{"key":"184_CR100","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett, T. et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol. Ther. 24, 1135\u20131149 (2016).","journal-title":"Mol. Ther."},{"issue":"Suppl. 1","key":"184_CR101","first-page":"556","volume":"132","author":"AM Li","year":"2018","unstructured":"Li, A. M. et al. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. Blood 132 (Suppl. 1), 556 (2018).","journal-title":"Blood"},{"key":"184_CR102","first-page":"577","volume":"130","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 130, 577 (2017).","journal-title":"Blood"},{"key":"184_CR103","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740\u2013753 (2016).","journal-title":"N. Engl. J. Med."},{"key":"184_CR104","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget, N. et al. Blinatumomab for minimal residual disease in adults with B cell precursor acute lymphoblastic leukemia. Blood 131, 1522\u20131531 (2018).","journal-title":"Blood"},{"key":"184_CR105","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"184_CR106","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli, G. et al. Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J. Clin. Oncol. 35, 1795\u20131802 (2017).","journal-title":"J. Clin. Oncol."},{"key":"184_CR107","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8\u2009+\u2009and CD4\u2009+\u2009CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl Med. 8, 355ra116 (2016).","journal-title":"Sci. Transl Med."},{"issue":"Suppl. 1","key":"184_CR108","first-page":"3889","volume":"130","author":"H Shalabi","year":"2017","unstructured":"Shalabi, H. et al. Intensification of lymphodepletion optimizes CAR re-treatment efficacy. Blood 130 (Suppl. 1), 3889 (2017).","journal-title":"Blood"},{"key":"184_CR109","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1182\/blood-2016-01-693887","volume":"128","author":"SL Maude","year":"2016","unstructured":"Maude, S. L. et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory acute lymphoblastic leukemia. Blood 128, 217 (2016).","journal-title":"Blood"},{"key":"184_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26594","volume":"64","author":"A Zoghbi","year":"2017","unstructured":"Zoghbi, A., Zur Stadt, U., Winkler, B., Muller, I. & Escherich, G. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. Pediatr. Blood Cancer 64, e26594 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"184_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0023-x","volume":"7","author":"E Mejstrikova","year":"2017","unstructured":"Mejstrikova, E. et al. CD19-negative relapse of pediatric B cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 7, 659 (2017).","journal-title":"Blood Cancer J."},{"key":"184_CR112","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ajh.24987","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour, E. et al. Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression. Am. J. Hematol. 93, 371\u2013374 (2018).","journal-title":"Am. J. Hematol."},{"key":"184_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0265-z","author":"D Bhojwani","year":"2018","unstructured":"Bhojwani, D. et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia https:\/\/doi.org\/10.1038\/s41375-018-0265-z (2018).","journal-title":"Leukemia"},{"key":"184_CR114","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"184_CR115","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","volume":"40","author":"J Fischer","year":"2017","unstructured":"Fischer, J. et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J. Immunother. 40, 187\u2013195 (2017).","journal-title":"J. Immunother."},{"key":"184_CR116","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"F Braig","year":"2017","unstructured":"Braig, F. et al. Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129, 100\u2013104 (2017).","journal-title":"Blood"},{"key":"184_CR117","doi-asserted-by":"publisher","first-page":"911","DOI":"10.4049\/jimmunol.1402346","volume":"194","author":"K Watanabe","year":"2015","unstructured":"Watanabe, K. et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8\u2009+\u2009T cells. J. Immunol. 194, 911\u2013920 (2015).","journal-title":"J. Immunol."},{"key":"184_CR118","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","volume":"25","author":"AJ Walker","year":"2017","unstructured":"Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol. Ther. 25, 2189\u20132201 (2017).","journal-title":"Mol. Ther."},{"key":"184_CR119","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso, H. G. et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 75, 3505\u20133518 (2015).","journal-title":"Cancer Res."},{"key":"184_CR120","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","volume":"103","author":"H Shalabi","year":"2018","unstructured":"Shalabi, H. et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T cell therapies in diffuse large B cell lymphoma. Haematologica 103, e215\u2013e218 (2018).","journal-title":"Haematologica"},{"key":"184_CR121","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute, G. et al. Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR T cells but results in antigen loss variants. Cancer Immunol. Res. 5, 571\u2013581 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"184_CR122","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"184_CR123","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl Med. 9, eaaa0984 (2017).","journal-title":"Sci. Transl Med."},{"key":"184_CR124","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3109\/10428194.2010.529206","volume":"52","author":"PP Piccaluga","year":"2011","unstructured":"Piccaluga, P. P. et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk. Lymphoma 52, 325\u2013327 (2011).","journal-title":"Leuk. Lymphoma"},{"key":"184_CR125","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","volume":"130","author":"I Nagel","year":"2017","unstructured":"Nagel, I. et al. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130, 2027\u20132031 (2017).","journal-title":"Blood"},{"key":"184_CR126","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","volume":"52","author":"S Raponi","year":"2011","unstructured":"Raponi, S. et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk. Lymphoma 52, 1098\u20131107 (2011).","journal-title":"Leuk. Lymphoma"},{"key":"184_CR127","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/pbc.25410","volume":"62","author":"NN Shah","year":"2015","unstructured":"Shah, N. N. et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr. Blood Cancer 62, 964\u2013969 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"184_CR128","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/leu.2008.303","volume":"23","author":"P Chevallier","year":"2009","unstructured":"Chevallier, P. et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia 23, 806\u2013807 (2009).","journal-title":"Leukemia"},{"issue":"Suppl. 2","key":"184_CR129","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.0960-135X.2004.01366.x","volume":"34","author":"G Mitterbauer-Hohendanner","year":"2004","unstructured":"Mitterbauer-Hohendanner, G. & Mannhalter, C. The biological and clinical significance of MLL abnormalities in haematological malignancies. Eur. J. Clin. Invest. 34 (Suppl. 2), 12\u201324 (2004).","journal-title":"Eur. J. Clin. Invest."},{"issue":"Suppl","key":"184_CR130","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1158\/1538-7445.AM2018-1630","volume":"78","author":"CD Chien","year":"2018","unstructured":"Chien, C. D. et al. FLT3 chimeric antigen receptor T cell therapy induces B to T cell lineage switch in infant acute lymphoblastic leukemia. Cancer Res. 78 (Suppl), 1630 (2018).","journal-title":"Cancer Res."},{"key":"184_CR131","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","volume":"5","author":"D Schneider","year":"2017","unstructured":"Schneider, D. et al. A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J. Immunother. Cancer 5, 42 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"184_CR132","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella, M. et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Invest. 126, 3814\u20133826 (2016).","journal-title":"J. Clin. Invest."},{"key":"184_CR133","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","volume":"11","author":"H Qin","year":"2018","unstructured":"Qin, H. et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol. Ther. Oncolyt. 11, 127\u2013137 (2018).","journal-title":"Mol. Ther. Oncolyt."},{"key":"184_CR134","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.bbmt.2017.12.018","volume":"24","author":"H Shalabi","year":"2018","unstructured":"Shalabi, H. et al. Chimeric antigen receptor T-cell (CAR-T) therapy can render patients with ALL into PCR-negative remission and can be an effective bridge to transplant (HCT). Biol. Blood Marrow Transplant. 24, S25\u2013S26 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"184_CR135","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2018-99-115599","volume":"132","author":"C Summers","year":"2018","unstructured":"Summers, C. et al. Long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR T cell induced remission. Blood 132, 967 (2018).","journal-title":"Blood"},{"key":"184_CR136","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy. Blood 130, 2295\u20132306 (2017).","journal-title":"Blood"},{"key":"184_CR137","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T cell therapy \u2014 assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"184_CR138","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"184_CR139","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter, D., Frey, N., Wood, P. A., Weng, Y. & Grupp, S. A. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J. Hematol. Oncol. 11, 35 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"184_CR140","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"184_CR141","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"184_CR142","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","volume":"16","author":"KM Mahadeo","year":"2018","unstructured":"Mahadeo, K. M. et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol. 16, 45\u201363 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"184_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","author":"DW Lee","year":"2018","unstructured":"Lee, D. W. et al. ASBMT Consensus Grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"184_CR144","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1182\/blood-2016-05-716910","volume":"128","author":"R Gardner","year":"2016","unstructured":"Gardner, R. et al. Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management. Blood 128, 586 (2016).","journal-title":"Blood"},{"key":"184_CR145","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.bbmt.2017.12.789","volume":"24","author":"MA Perales","year":"2018","unstructured":"Perales, M. A., Kebriaei, P., Kean, L. S. & Sadelain, M. Reprint of: building a safer and faster CAR: seatbelts, airbags, and CRISPR. Biol. Blood Marrow Transplant. 24, S15\u2013S19 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"184_CR146","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1002\/ajh.24594","volume":"92","author":"H Yu","year":"2017","unstructured":"Yu, H. et al. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am. J. Hematol. 92, E11\u2013E13 (2017).","journal-title":"Am. J. Hematol."},{"key":"184_CR147","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer, J. N. et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol. Ther. 25, 2245\u20132253 (2017).","journal-title":"Mol. Ther."},{"issue":"Suppl","key":"184_CR148","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","volume":"130","author":"L Budde","year":"2017","unstructured":"Budde, L. et al. Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Blood 130 (Suppl), 811 (2017).","journal-title":"Blood"},{"issue":"Suppl.","key":"184_CR149","first-page":"O-100","volume":"65","author":"L Yang","year":"2018","unstructured":"Yang, L. et al. Preclinical efficacy of CD33 chimeric antigen receptor T cell immunotherapy in childhood acute myeloid leukemia. Pediatr. Blood Cancer 65 (Suppl.), O-100 (2018).","journal-title":"Pediatr. Blood Cancer"},{"key":"184_CR150","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.3389\/fimmu.2018.02593","volume":"9","author":"A Schmidts","year":"2018","unstructured":"Schmidts, A. & Maus, M. V. Making CAR T cells a solid option for solid tumors. Front. Immunol. 9, 2593 (2018).","journal-title":"Front. Immunol."},{"key":"184_CR151","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3389\/fimmu.2018.02493","volume":"9","author":"MA Morgan","year":"2018","unstructured":"Morgan, M. A. & Schambach, A. Engineering CAR-T cells for improved function against solid tumors. Front. Immunol. 9, 2493 (2018).","journal-title":"Front. Immunol."},{"key":"184_CR152","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","volume":"9","author":"K Watanabe","year":"2018","unstructured":"Watanabe, K., Kuramitsu, S., Posey, A. D. Jr & June, C. H. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front. Immunol. 9, 2486 (2018).","journal-title":"Front. Immunol."},{"key":"184_CR153","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1200\/EDBK_200773","volume":"38","author":"C DeRenzo","year":"2018","unstructured":"DeRenzo, C., Krenciute, G. & Gottschalk, S. The landscape of CAR T cells beyond acute lymphoblastic leukemia for pediatric solid tumors. Am. Soc. Clin. Oncol. Educ. Book 38, 830\u2013837 (2018).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"184_CR154","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","volume":"20","author":"SS Kachala","year":"2014","unstructured":"Kachala, S. S. et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin. Cancer Res. 20, 1020\u20131028 (2014).","journal-title":"Clin. Cancer Res."},{"key":"184_CR155","first-page":"5238","volume":"9","author":"P Heinmoller","year":"2003","unstructured":"Heinmoller, P. et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin. Cancer Res. 9, 5238\u20135243 (2003).","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 1","key":"184_CR156","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s12032-010-9752-4","volume":"28","author":"D Situ","year":"2011","unstructured":"Situ, D. et al. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med. Oncol. 28 (Suppl. 1), 596\u2013604 (2011).","journal-title":"Med. Oncol."},{"key":"184_CR157","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050\u20136056 (2011).","journal-title":"Blood"},{"key":"184_CR158","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","volume":"4","author":"AH Long","year":"2016","unstructured":"Long, A. H. et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4, 869\u2013880 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"184_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D. & Brentjens, R. J. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 7, 10541 (2017).","journal-title":"Sci. Rep."},{"key":"184_CR160","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi, M. P. et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 23, 2130\u20132141 (2018).","journal-title":"Cell Rep."},{"key":"184_CR161","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown, C. E. et al. Optimization of IL13Ralpha2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol. Ther. 26, 31\u201344 (2018).","journal-title":"Mol. Ther."},{"key":"184_CR162","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(\u2009+\u2009) diffuse midline gliomas. Nat. Med. 24, 572\u2013579 (2018).","journal-title":"Nat. Med."},{"key":"184_CR163","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","volume":"6","author":"A Nellan","year":"2018","unstructured":"Nellan, A. et al. Durable regression of medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J. Immunother. Cancer 6, 30 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"184_CR164","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094\u20131101 (2017).","journal-title":"JAMA Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0184-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0184-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0184-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:27:57Z","timestamp":1684607277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-019-0184-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":164,"alternative-id":["184"],"URL":"https:\/\/doi.org\/10.1038\/s41571-019-0184-6","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735242514.793560913","asserted-by":"object"}]},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,5]]},"assertion":[{"value":"5 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}